List of Excipients in Branded Drug ASPRUZYO SPRINKLE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
SUN PHARMACEUTICAL INDUSTRIES INC	ASPRUZYO SPRINKLE	ranolazine	47335-624	CELLULOSE, MICROCRYSTALLINE
SUN PHARMACEUTICAL INDUSTRIES INC	ASPRUZYO SPRINKLE	ranolazine	47335-624	DIBUTYL SEBACATE
SUN PHARMACEUTICAL INDUSTRIES INC	ASPRUZYO SPRINKLE	ranolazine	47335-624	DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER
SUN PHARMACEUTICAL INDUSTRIES INC	ASPRUZYO SPRINKLE	ranolazine	47335-624	ETHYLCELLULOSE
SUN PHARMACEUTICAL INDUSTRIES INC	ASPRUZYO SPRINKLE	ranolazine	47335-624	HYPROMELLOSE
SUN PHARMACEUTICAL INDUSTRIES INC	ASPRUZYO SPRINKLE	ranolazine	47335-624	MAGNESIUM STEARATE

Aspruzyo Sprinkle Excipient Strategy and Commercial Opportunities

Last updated: October 2, 2026

Aspruzyo Sprinkle is an oral-granule formulation of valsartan designed to address patients who cannot reliably swallow conventional tablets. Its commercial value is concentrated in pediatric hypertension, adult heart-failure patients with dysphagia, caregiver administration, and institutional use. The formulation’s defensibility depends less on valsartan, which is an established generic active ingredient, and more on granule engineering, dose flexibility, administration instructions, stability, taste control, and regulatory protection for the dosage form.

What is Aspruzyo Sprinkle and who manufactures it?

Aspruzyo Sprinkle contains valsartan, an angiotensin II receptor blocker. It is supplied as oral granules in 40 mg, 80 mg, and 160 mg strengths. The product is indicated for hypertension in pediatric patients aged 1 to less than 17 years and for adult heart failure, including use to reduce cardiovascular mortality and heart-failure hospitalization in appropriate patients. [1]

The product is marketed in the United States by Sun Pharmaceutical Industries, Inc. The product is regulated under a New Drug Application rather than as a conventional valsartan tablet ANDA. That distinction reflects the product’s novel oral-granule dosage form and its clinical and regulatory positioning.

Attribute	Aspruzyo Sprinkle
Active ingredient	Valsartan
Drug class	Angiotensin II receptor blocker
Dosage form	Oral granules
Strengths	40 mg, 80 mg, 160 mg
Pediatric use	Hypertension, ages 1 to less than 17 years
Adult use	Heart failure and hypertension
Administration	Granules sprinkled on soft food
Primary differentiation	Swallowing-independent oral administration
U.S. sponsor/marketer	Sun Pharmaceutical Industries, Inc.
Regulatory pathway	NDA
Reference sources	FDA prescribing information; DailyMed

What excipients are used in Aspruzyo Sprinkle?

The FDA labeling identifies inactive ingredients that support granule formation, flow, dispersion, mechanical integrity, and manufacturability. The listed excipients include microcrystalline cellulose, crospovidone, hypromellose, colloidal silicon dioxide, sodium lauryl sulfate, magnesium stearate, and talc. [1,2]

Excipient	Likely formulation function
Microcrystalline cellulose	Diluent, granule matrix, compressibility and structural support
Crospovidone	Disintegrant and dispersion aid
Hypromellose	Binder, film-forming or release-control support
Colloidal silicon dioxide	Glidant and moisture-management aid
Sodium lauryl sulfate	Wetting agent and dissolution-support excipient
Magnesium stearate	Lubricant
Talc	Processing aid, anti-adherent, or surface-property modifier

The commercial objective is not simply to maximize dissolution. The excipient system must produce granules that remain discrete during packaging and transport, disperse rapidly on soft food, limit powder segregation, and avoid excessive residue in the dosing container.

Why microcrystalline cellulose matters

Microcrystalline cellulose provides a relatively inert, widely accepted structural base. In an oral-granule product, it can improve granule strength without creating a high-viscosity suspension. Excessive levels, however, may increase mouthfeel, residue, and the risk that patients perceive the product as gritty.

Why crospovidone and sodium lauryl sulfate matter

Valsartan has formulation challenges related to aqueous solubility and dissolution behavior. Crospovidone can accelerate wetting and breakup of the granule matrix. Sodium lauryl sulfate can improve wetting, but its concentration must be controlled because surfactant-related taste, irritation, and food-interaction issues can reduce acceptability.

Why hypromellose is commercially relevant

Hypromellose can improve granule cohesion and help control the release of valsartan from the granule matrix. It also provides a platform for future formulation changes, including taste-masked granules, modified-release products, or multiparticulate combinations. A higher-viscosity system could impair dispersion and make dosing less consistent, so the polymer grade is a potentially important process variable.

Why colloidal silicon dioxide and magnesium stearate matter

Both excipients are primarily manufacturing enablers. Colloidal silicon dioxide can improve flow and reduce processing variability. Magnesium stearate supports equipment performance but can interfere with wetting or dissolution if over-lubrication occurs. This creates a formulation trade-off between manufacturability and drug release.

What formulation attributes are protected by Aspruzyo Sprinkle?

The principal protected product concept is the oral-granule delivery system rather than the valsartan molecule. Relevant technical attributes include:

1. Granule size distribution.
2. Valsartan loading per granule.
3. Dispersion on soft food.
4. Dose uniformity across the sachet or unit dose.
5. Dissolution and disintegration performance.
6. Moisture protection.
7. Stability under shipping and storage conditions.
8. Acceptable taste and mouthfeel.
9. Low dust generation during administration.
10. Compatibility with pediatric dosing practices.

These attributes create a higher development burden than a conventional immediate-release tablet. A competing product must demonstrate pharmaceutical equivalence or establish its own clinical and regulatory bridge, depending on the pathway used.

How is Aspruzyo Sprinkle administered?

The product is intended to be sprinkled on a small amount of soft food and consumed immediately. The granules should not be chewed or crushed. The labeling is designed to avoid the need for tablet swallowing, which is particularly relevant for young children and patients with dysphagia. [1]

Administration instructions are part of the product’s commercial value. A formulation that can be used with common soft foods, has limited bitterness, and leaves minimal residue can improve adherence. A product that requires extensive preparation, water suspension, or administration through specialized devices would compete less effectively in outpatient pediatric care.

The current dosage form should not automatically be treated as a tube-feeding product. Nasogastric or gastrostomy administration requires specific compatibility, recovery, clogging, and dose-delivery data. Without product-specific validation, tube administration is a commercial risk rather than an established use case.

What are the strongest commercial opportunities?

Pediatric hypertension

The clearest market opportunity is pediatric hypertension. Conventional valsartan tablets create swallowing and dose-flexibility problems in younger children. Aspruzyo Sprinkle allows administration without requiring the child to swallow a tablet.

Potential customers include:

• Pediatric cardiology practices.
• Pediatric nephrology clinics.
• Specialty pharmacies.
• Children’s hospitals.
• Caregivers managing chronic medication at home.

The addressable patient population is smaller than the adult hypertension market, but pediatric prescribing is less exposed to direct substitution by ordinary valsartan tablets. That can support a premium for convenience and adherence.

Adult dysphagia and heart failure

Adult heart-failure patients may have dysphagia, frailty, stroke-related swallowing impairment, cognitive limitations, or polypharmacy. A sprinkle formulation provides a potential administration option when tablets are difficult to use.

The principal commercial challenge is that adult heart-failure treatment is crowded with low-cost generic ARBs, ACE inhibitors, sacubitril/valsartan, beta blockers, mineralocorticoid receptor antagonists, and other therapies. The product must therefore compete on administration access rather than on pharmacologic novelty.

Hospital and post-acute care

Hospitals, rehabilitation facilities, long-term-care facilities, and home-health providers may value a formulation that reduces tablet crushing and simplifies medication administration. The opportunity is strongest where medication-error reduction or swallowing limitations influence formulary decisions.

Institutional adoption will depend on:

• Unit-dose packaging.
• Pharmacy workflow.
• Storage requirements.
• Food compatibility.
• Dose preparation time.
• Insurance reimbursement.
• Whether the product can replace liquid extemporaneous compounding.

Extemporaneous-compounding substitution

Some pediatric patients receive compounded valsartan liquids. A ready-to-use granule product can compete with compounding when pharmacies or caregivers face stability, flavoring, concentration, or supply problems.

The commercial advantage is strongest where the product offers predictable potency and a standardized dose. The limitation is price. Compounded liquids may remain cheaper for high-volume patients, particularly when reimbursement does not recognize the administration benefit.

How does Aspruzyo Sprinkle compare with competing valsartan products?

Product type	Main advantage	Main weakness	Competitive position
Valsartan tablets	Low price and broad availability	Swallowing barrier; limited pediatric flexibility	Strong in routine adult use
Valsartan oral solution compounded by pharmacy	Flexible concentration and liquid administration	Stability, flavor, labor, and quality variability	Relevant in pediatrics
Aspruzyo Sprinkle	No tablet swallowing; standardized granules	Higher cost and administration restrictions	Strongest in pediatric and dysphagia segments
Other pediatric liquid ARBs	Familiar liquid administration	Different active ingredient, taste, and dosing profile	Indication and formulary dependent
Sacubitril/valsartan formulations	Heart-failure efficacy and combination therapy	Higher cost and different clinical positioning	Strong adult competitor, not a direct dosage-form substitute

Aspruzyo Sprinkle is not likely to displace low-cost valsartan tablets across the general hypertension market. Its realistic strategy is segmentation: patients who cannot swallow tablets, caregivers who need simple administration, and prescribers seeking a standardized alternative to compounded liquid valsartan.

What FDA exclusivity and Orange Book issues affect the product?

Valsartan itself has long lost basic compound exclusivity. The relevant protections are therefore dosage-form, formulation, method-of-use, and regulatory exclusivities.

The FDA Orange Book and Drugs@FDA records are the controlling sources for listed patents, exclusivity codes, and approved labeling. [3,4] Commercial diligence should distinguish among:

• Active ingredient patents, which are unlikely to provide meaningful protection for valsartan.
• Formulation patents covering oral granules or multiparticulate delivery.
• Manufacturing patents covering granulation, coating, or moisture control.
• Method-of-use patents covering specific patient populations or administration methods.
• Three-year exclusivity associated with new clinical investigations supporting approval, if listed by FDA.
• Pediatric exclusivity, if separately granted and applicable.

The product’s NDA status does not prevent all generic competition. A competing manufacturer could pursue an ANDA if it can satisfy FDA requirements for the dosage form, or use a different regulatory strategy if it develops a clinically distinct product. The commercial barrier is likely to be formulation development and regulatory evidence rather than valsartan supply.

Are Paragraph IV challenges and generic entry risks material?

Potential generic entry risks are moderate to high over the long term and lower in the initial period if formulation claims and regulatory exclusivity remain effective.

A Paragraph IV challenge could target listed patents covering:

• Granule composition.
• Particle-size distribution.
• Drug loading.
• Taste masking.
• Administration with food.
• Packaging or moisture protection.
• Manufacturing processes.

A generic applicant would likely prioritize a formulation that avoids the most commercially important claims while matching the reference product’s performance. The greatest vulnerability would arise if the Orange Book contains few formulation patents or if listed claims cover narrow process features that can be designed around.

Generic launch scenarios include:

Scenario	Likely commercial effect
No early challenge	Sun retains pediatric and dysphagia differentiation
Paragraph IV challenge without settlement	Litigation costs and potential at-risk launch
Successful design-around	Price pressure, particularly in adult use
Authorized generic	Faster price erosion with controlled channel strategy
Competing liquid ARB	Segment erosion without direct equivalence
Competing sprinkle valsartan	Direct erosion of the product’s core value proposition

Because valsartan tablets are already inexpensive, the product’s premium depends on the absence of a clinically and administratively equivalent sprinkle competitor.

What licensing and partnering opportunities exist?

The most attractive partnering opportunities are likely commercial rather than molecule-based.

Pediatric specialty-pharmacy partnerships

Pediatric specialty pharmacies can support prior authorization, caregiver education, refill adherence, and dose titration. These services can protect the product from substitution by tablets or compounded liquids.

Contract manufacturing and granulation technology

Manufacturers with expertise in wet granulation, dry granulation, multiparticulates, coating, and low-dose uniformity may be useful for regional supply, dual sourcing, or future lifecycle products.

Hospital formulary agreements

Institutional agreements could position the product as an alternative to tablet crushing or pharmacy-compounded valsartan. The value proposition should focus on administration reliability, workflow, and reduced preparation burden.

Lifecycle licensing

Potential follow-on products include:

• Valsartan granules for validated enteral-tube use.
• Lower-dose pediatric strengths.
• Taste-masked granules.
• Unit-dose stick packs.
• Fixed-dose pediatric cardiovascular combinations.
• Granules compatible with a broader range of foods.
• Co-packaged titration kits.

Any lifecycle strategy must avoid creating a product that is easier to administer but more difficult to manufacture, reimburse, or substitute under FDA rules.

How strong is the patent estate for Aspruzyo Sprinkle?

The commercial patent position is likely strongest where claims cover the complete product architecture: valsartan granules, excipient ratios, particle-size distribution, performance specifications, packaging, and administration method.

It is weaker where protection depends only on:

• Generic excipients used broadly across the industry.
• Conventional granulation steps.
• Valsartan itself.
• Broad method-of-use claims that do not distinguish the oral-granule dosage form.
• Narrow manufacturing parameters that competitors can avoid.

The practical moat is therefore a combination of patents, FDA exclusivity, manufacturing know-how, taste and handling performance, pediatric prescriber adoption, and payer positioning. A patent-only assessment would understate the product’s commercial defenses, while a formulation-only assessment would overstate them.

Key Takeaways

• Aspruzyo Sprinkle’s active ingredient, valsartan, is commoditized; the commercial asset is the oral-granule delivery system.
• The key patient segments are children with hypertension, adults with dysphagia, and institutional patients who cannot reliably swallow tablets.
• Microcrystalline cellulose, crospovidone, hypromellose, colloidal silicon dioxide, sodium lauryl sulfate, magnesium stearate, and talc support granule integrity, flow, wetting, dissolution, and processing.
• The main formulation risks are bitterness, grittiness, dose nonuniformity, moisture sensitivity, residue, and inadequate food compatibility.
• The product competes less against ordinary valsartan tablets than against compounded liquid valsartan and other pediatric administration options.
• Generic risk will depend on Orange Book-listed formulation patents, FDA exclusivity, and whether competitors can design around granule and administration claims.
• The strongest commercial opportunities are pediatric specialty pharmacy, hospital formulary adoption, dysphagia care, and substitution for extemporaneously compounded valsartan liquids.
• Future value could come from validated enteral-tube administration, improved taste masking, lower pediatric strengths, and fixed-dose cardiovascular combinations.

FAQs

Can Aspruzyo Sprinkle replace compounded valsartan liquid?

It can be a standardized alternative for some patients, but it is not automatically interchangeable with every compounded liquid. Administration instructions, dose requirements, food compatibility, and payer coverage determine substitution.

Is Aspruzyo Sprinkle a generic valsartan product?

No. It is an NDA-approved oral-granule product. Its regulatory position differs from conventional valsartan tablet ANDA products.

Can Aspruzyo Sprinkle be crushed or chewed?

No. The granules are intended to be sprinkled on soft food and consumed according to the FDA-approved instructions. Crushing or chewing can change administration performance.

Is Aspruzyo Sprinkle approved for feeding-tube administration?

The approved labeling does not establish broad feeding-tube use. Tube administration should not be treated as an approved commercial indication without product-specific FDA-supported data.

What is the primary investment risk for Aspruzyo Sprinkle?

The principal risk is limited market size combined with competition from inexpensive tablets, compounded liquids, and future sprinkle or liquid ARB products. The product’s economics depend on maintaining a meaningful administration advantage and securing reimbursement for that advantage.

References

1. U.S. Food and Drug Administration. (n.d.). Aspruzyo Sprinkle (valsartan) oral granules: Prescribing information.
2. National Library of Medicine. (n.d.). Aspruzyo Sprinkle- valsartan granule. DailyMed.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.